91 related articles for article (PubMed ID: 12107842)
21. The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014.
Ascierto PA; Addeo R; Cartenì G; Daniele B; De Laurentis M; Ianniello GP; Morabito A; Palmieri G; Pepe S; Perrone F; Pignata S; Montesarchio V
J Transl Med; 2014 Oct; 12():291. PubMed ID: 25331657
[TBL] [Abstract][Full Text] [Related]
22. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Omlin A; Pezaro C; Atenafu EG; Keizman D; Vera-Badillo F; Seah JA; Attard G; Knox JJ; Sridhar SS; Tannock IF; de Bono JS; Joshua AM
Ann Oncol; 2014 Mar; 25(3):657-662. PubMed ID: 24458472
[TBL] [Abstract][Full Text] [Related]
23. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.
Porrata LF; Ristow K; Colgan JP; Habermann TM; Witzig TE; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN
Haematologica; 2012 Feb; 97(2):262-9. PubMed ID: 21993683
[TBL] [Abstract][Full Text] [Related]
24. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer.
Vlad AM; Budiu RA; Lenzner DE; Wang Y; Thaller JA; Colonello K; Crowley-Nowick PA; Kelley JL; Price FV; Edwards RP
Cancer Immunol Immunother; 2010 Feb; 59(2):293-301. PubMed ID: 19690855
[TBL] [Abstract][Full Text] [Related]
25. Inhaled IL-2 induces systemic immunomodulation in patients with renal cell carcinoma and lung metastasis.
Diaz D; Chara L; Chevarria J; Carballido J; Esteban E; Navas V; Monserrat J; Prieto A; de la Hera A; Alvarez-Mon M
Cancer Immunol Immunother; 2009 Feb; 58(2):235-45. PubMed ID: 18592236
[TBL] [Abstract][Full Text] [Related]
26. Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival.
Jeong IG; Han KS; Joung JY; Choi WS; Hwang SS; Yang SO; Seo HK; Chung J; Lee KH
J Korean Med Sci; 2007 Sep; 22 Suppl(Suppl):S122-8. PubMed ID: 17923738
[TBL] [Abstract][Full Text] [Related]
27. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.
Klatte T; Ittenson A; Röhl FW; Ecke M; Allhoff EP; Böhm M
Br J Cancer; 2006 Nov; 95(9):1167-73. PubMed ID: 17031403
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy of renal cell carcinoma.
Gouttefangeas C; Stenzl A; Stevanović S; Rammensee HG
Cancer Immunol Immunother; 2007 Jan; 56(1):117-28. PubMed ID: 16676181
[TBL] [Abstract][Full Text] [Related]
29. Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial.
Donskov F; Hokland M; Marcussen N; Torp Madsen HH; von der Maase H
Br J Cancer; 2006 Jan; 94(2):218-26. PubMed ID: 16434984
[TBL] [Abstract][Full Text] [Related]
30. In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma.
Donskov F; Marcussen N; Hokland M; Fisker R; Madsen HH; von der Maase H
Br J Cancer; 2004 Feb; 90(3):626-31. PubMed ID: 14760375
[TBL] [Abstract][Full Text] [Related]
31. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
[TBL] [Abstract][Full Text] [Related]
32. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
Hermann GG
APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
[No Abstract] [Full Text] [Related]
33. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
34. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
Donskov F; Bennedsgaard KM; Von Der Maase H; Marcussen N; Fisker R; Jensen JJ; Naredi P; Hokland M
Br J Cancer; 2002 Jul; 87(2):194-201. PubMed ID: 12107842
[TBL] [Abstract][Full Text] [Related]
35. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
36. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
